Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonsteroid immune modulators and bone disease.

Ronald Tamler1, Solomon Epstein

  • 1Mount Sinai School of Medicine, New York, NY 10029, USA.

Annals of the New York Academy of Sciences
|July 13, 2006
PubMed
Summary

Newer immunosuppressive drugs, including calcineurin inhibitors (CIs), can cause severe bone loss after organ transplantation. Further research is needed to understand and mitigate these bone health risks in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Healthcare utilization impacts of an eConsult program for headache at an academic medical center.

Journal of telemedicine and telecare·2023
Same author

Internet-Based Health Care Communication Among Cancer Survivors, 2011-2018 National Health Interview Survey.

Preventing chronic disease·2021
Same author

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.

Journal of the American College of Cardiology·2020
Same author

Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass.

Proceedings of the National Academy of Sciences of the United States of America·2020
Same author

Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?

Cardiovascular drugs and therapy·2019
Same author

Insulin resistance and bone: a biological partnership.

Acta diabetologica·2018

Area of Science:

  • Immunology
  • Pharmacology
  • Orthopedics

Background:

  • Glucocorticoids are primary agents for preventing organ rejection but have severe side effects.
  • Newer immunosuppressive agents improve transplant outcomes but can cause significant bone loss.
  • Calcineurin inhibitors (CIs), like cyclosporine and tacrolimus, are associated with rapid and severe bone loss.

Purpose of the Study:

  • To investigate the bone health effects of immunosuppressive agents used in organ transplantation.
  • To explore the mechanisms behind CI-induced bone loss, potentially involving T lymphocytes and RANKL.
  • To assess the clinical incidence of fractures and bone loss in transplant recipients.

Main Methods:

  • Review of existing literature on immunosuppressive drugs and bone metabolism in transplant patients.
  • Analysis of in vitro and in vivo studies examining the effects of CIs on bone.
  • Clinical observation of fracture incidence and bone disease in organ transplant recipients.

Main Results:

  • Calcineurin inhibitors (CIs) induce acute, rapid, and severe bone loss (ARSBL) in both animal models and humans.
  • The mechanism of CI-induced bone loss is complex and may involve T lymphocyte action via RANKL.
  • High incidence of fractures is observed in transplant patients, influenced by transplant type, pre-existing conditions, and drug regimens.
  • Other immunosuppressants (azathioprine, mycophenolate mofetil, sirolimus) have not shown bone loss effects.

Conclusions:

  • Calcineurin inhibitors pose a significant risk for bone loss and fractures in organ transplant recipients.
  • The precise mechanism of CI-induced bone loss requires further elucidation, particularly the role of immune mediators.
  • Except for glucocorticoids, all discussed immunosuppressive agents warrant further investigation regarding their long-term clinical effects on bone health.

Related Experiment Videos